Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists

Summary

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs are relatively new and high-profile classes of medicines that are used to treat type 2 diabetes mellitus (T2DM) and/or obesity.

The GLP-1 RAs currently marketed in Australia include:

• Ozempic (semaglutide), Trulicity (dulaglutide) and Victoza (liraglutide), which are approved for the management of adults with T2DM.
• Saxenda (liraglutide) and Wegovy (semaglutide), which are approved for chronic weight management in patients who are obese or overweight.

The dual GIP/GLP-1 RA currently marketed in Australia:

• Mounjaro (tirzepatide) is approved for both T2DM and chronic weight management.

There is a known potential for all medicines in these classes to delay passage of food through the stomach (gastric emptying).

This poses a potential risk for patients during general anaesthesia or deep sedation as the usual fasting period beforehand may not be sufficient to empty the stomach.

We have required updates to Product Information (PI) and Consumer Medicine Information (CMI) documents for all these medicines with a warning about the risk of accidentally inhaling stomach contents during general anaesthesia or deep sedation.

Trulicity and Ozempic are available on the PBS (authority streamlined).

What health professionals should do

Be alert to the class-wide warning being added to the PIs for these medicines about the risk of pulmonary aspiration during general anaesthesia or deep sedation.

Advise patients of the risk and to alert health professionals, including anaesthetists, that they are taking one of these medicines before a surgical procedure to ensure appropriate management.

Anaesthetists should:

• be particularly alert that residual gastric contents may remain despite preoperative fasting in patients taking these medicines
• ask patients whether they are taking one of these medicines
• consider the risk of aspiration in patients taking these medicines within the preoperative risk assessment, so it can be managed appropriately.

Information for consumers

Patients are advised to tell health professionals, including anaesthetists, that they are taking one of these medicines before a surgery or other procedures.

Background

In 2023, the TGA conducted an independent assessment following sponsor notification of a safety signal from the US Food and Drug Administration (FDA) regarding aspiration during general anaesthesia (GA) and deep sedation for these medicines.

We approved updates to the PIs of all 3 GLP-1 receptor agonists on the ARTG (dulaglutide, liraglutide and semaglutide; under 5 tradenames) and one dual GIP/GLP-1 receptor agonist (tirzepatide) to include a precaution in section 4.4 for aspiration during GA and deep sedation.

Delayed gastric emptying, which is a risk factor for aspiration, was already a recognised effect described in the PI of all these medicines.

Adverse events reported to us

A search of our publicly available Database of Adverse Event Notification (DAEN) on 14 May 2025 for the GLP-1 and dual GIP/GLP-1 receptor agonists identified 7 cases for aspiration and 1 case of pneumonia aspiration for semaglutide, 1 case of aspiration and 1 case of pneumonia aspiration for liraglutide and 1 case of pneumonia aspiration for dulaglutide. All cases were reported with a single suspected medicine.

Changes to the PI

The following warning has been added to the PIs for Trulicity (dulaglutide), Victoza (liraglutide), Saxenda (liraglutide), Ozempic (semaglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide):

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE:

Aspiration in association with general anaesthesia or deep sedation

Cases of pulmonary aspiration have been reported in patients receiving GLP-1 RAs undergoing general anaesthesia (GA) or deep sedation despite reported adherence to preoperative fasting recommendations. Therefore, the increased risk of residual gastric content because of delayed gastric emptying should be considered prior to performing procedures with GA or deep sedation.

Relevant literature

• MHRA drug safety update GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation.

Disclaimer

Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.

© Commonwealth of Australia 2025

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to tga.copyright@tga.gov.au.

For the latest safety information from us, subscribe to the TGA Safety Information email list via our website.

For correspondence or further information about Medicines Safety Update visit Contact us | Therapeutic Goods Administration (TGA).

Medicines Safety Update is written by staff from the Pharmacovigilance Branch.

• Editor: Dr Daniel Dascombe
• Deputy Editor: Aaron Hall
• Contributor: My Di Luu